Literature DB >> 9213245

Immunological evaluation in oral lichen planus with chronic hepatitis C.

Y Nagao1, M Sata, K Abe, K Tanikawa, T Kameyama.   

Abstract

Oral lichen planus (OLP) is frequently associated with hepatitis C virus (HCV) infection. We have previously reported that the pathogenesis of OLP arises from host rather than viral factors. In this study, we investigated the role of these factors in 41 patients with chronic hepatitis C: 22 with OLP (group 1) and 19 without OLP (group 2). All patients had antibodies to HCV (anti-HCV) and were serum HCV RNA-positive; none were HBsAg-positive. Immune abnormalities in serum were evaluated by testing for antinuclear antibody (ANA), rheumatoid factor (RF) activity, immunoglobulins (IgG, IgM, and IgA), and cryoglobulin. The rate for ANA positivity and IgM levels were significantly higher in group 1 than in group 2 (P < 0.05). Mean age in group 1 was significantly higher in group 2 (P = 0.0001). Of the factors tested, ANA, IgM, and age, logistic regression showed that age correlated independently with OLP (P = 0.003). In 5 patients in group 1, the infiltrating lymphocytic subsets of the OLP lesion were examined histopathologically. Predominant T cell infiltration was shown in all 5 patients. In addition to host factors, wer also examined viral factors in both groups of patients, measuring serum HCV RNA level and determining HCV genotype. There were no significant differences between the groups in these viral factors. This study suggested that host factors induced by the HCV infection are more important than viral factors in the pathogenesis of OLP associated with hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9213245     DOI: 10.1007/bf02934488

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  33 in total

1.  Lichen planus: immunologic and morphologic identification of the submucosal infiltrate.

Authors:  J A Regezi; M J Deegan; J R Hayward
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1978-07

2.  Histochemical identification of T cells in oral lichen planus.

Authors:  H M Dockrell; J S Greenspan
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1979-07

3.  Serum IgG, IgA, IgM, IgD and IgE in lichen planus: no evidence for a humoral immunodeficiency.

Authors:  C Scully
Journal:  Clin Exp Dermatol       Date:  1982-03       Impact factor: 3.470

4.  Development of rheumatoid arthritis after chronic hepatitis caused by hepatitis C virus infection.

Authors:  S Hirohata; T Inoue; K Ito
Journal:  Intern Med       Date:  1992-04       Impact factor: 1.271

5.  Direct immunofluorescence in oral lichen planus.

Authors:  G Laskaris; A Sklavounou; A Angelopoulos
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1982-05

6.  Quantitative analysis of HCV RNA and genotype in patients with chronic hepatitis C accompanied by oral lichen planus.

Authors:  Y Nagao; M Sata; K Itoh; K Tanikawa; T Kameyama
Journal:  Eur J Clin Invest       Date:  1996-06       Impact factor: 4.686

7.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.

Authors:  R Misiani; P Bellavita; D Fenili; G Borelli; D Marchesi; M Massazza; G Vendramin; B Comotti; E Tanzi; G Scudeller
Journal:  Ann Intern Med       Date:  1992-10-01       Impact factor: 25.391

8.  Lichen planus and hepatitis C virus--related chronic active hepatitis.

Authors:  C Jubert; J M Pawlotsky; F Pouget; C Andre; L DeForges; S Bretagne; J P Mavier; J Duval; J Revuz; D Dhumeaux
Journal:  Arch Dermatol       Date:  1994-01

9.  Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C.

Authors:  U Protzer; F R Ochsendorf; A Leopolder-Ochsendorf; K H Holtermüller
Journal:  Gastroenterology       Date:  1993-03       Impact factor: 22.682

10.  Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection.

Authors:  M Kurosaki; N Enomoto; F Marumo; C Sato
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.